Parkinson's Disease

Potential FDA approval for Supernus’s SPN-830 in Parkinson’s but challenges remain
Potential FDA approval for Supernus’s SPN-830 in Parkinson’s but challenges remain
Clinical Trials Arena
Supernus
SPN-830
Parkinson's Disease
FDA
Flag link:
Stem Pharm and Verge Genomics Form Collaboration Focused on Parkinson’s Disease
Stem Pharm and Verge Genomics Form Collaboration Focused on Parkinson’s Disease
BioSpace
Stem Pharm
Verge Genomics
Parkinson's Disease
artificial intelligence
Flag link:
Months after FDA slam, AbbVie buys Parkinson’s disease drugmaker Mitokinin
Months after FDA slam, AbbVie buys Parkinson’s disease drugmaker Mitokinin
Medical Marketing and Media
AbbVie
M&A
Mitokinin
Parkinson's Disease
Flag link:
Bayer Pushes Ahead With Parkinson’s Cell Therapy on Heels of Positive Phase 1 Data
Bayer Pushes Ahead With Parkinson’s Cell Therapy on Heels of Positive Phase 1 Data
MedCity News
Bayer
cell therapy
Parkinson's Disease
clinical trials
Flag link:
Bayer preps for phase 2 after Parkinson's cell therapy clears safety bar in early-stage study
Bayer preps for phase 2 after Parkinson's cell therapy clears safety bar in early-stage study
Fierce Biotech
Bayer
Parkinson's Disease
cell therapy
bemdaneprocel
BlueRock Therapeutics
Flag link:
Aspen taps tech firms for digital Parkinson's trial
Aspen taps tech firms for digital Parkinson's trial
Pharmaphorum
Apen Neuroscience
Parkinson's Disease
cell therapy
Emerald Innovations
Rune Labs
Flag link:
Bayer-bought BlueRock cuts 12% of workforce across 3 sites as pipeline contracts
Bayer-bought BlueRock cuts 12% of workforce across 3 sites as pipeline contracts
Fierce Biotech
BlueRock Therapeutics
Parkinson's Disease
Bayer
layoffs
Flag link:
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
BioSpace
neurodegenerative disease
Alzheimer's disease
Axsome Therapeutics
Eli Lilly
Anavex
TauRx
AB Science
ALS
BrainStorm Cell Therapeutics
Seelos Therapeutics
Parkinson's Disease
AbbVie
Mitsubishi Tanabe Pharma
Annovis
Huntington's disease
Prilenia Therapeutics
Neurocrine
Flag link:
Boston Scientific’s New Deep Brain Stimulation Software Gets FDA Nod
Boston Scientific’s New Deep Brain Stimulation Software Gets FDA Nod
Xtalks
Boston Scientific
Medtech
deep brain stimulation
Vercise Deep Brain Stimulation System
FDA
Parkinson's Disease
Flag link:
Amneal’s long-acting Parkinson’s drug gets cold shoulder from FDA
Amneal’s long-acting Parkinson’s drug gets cold shoulder from FDA
Medical Marketing and Media
Amneal Pharmaceuticals
FDA
Parkinson's Disease
IPX203
Flag link:
Bayer's Parkinson's cell therapy passes early clinical safety test, clearing path to phase 2
Bayer's Parkinson's cell therapy passes early clinical safety test, clearing path to phase 2
Fierce Biotech
Bayer
Parkinson's Disease
clinical trials
cell therapy
bemdaneprocel
Flag link:
Vaxxinity celebrates trial success in early Parkinson’s therapy
Vaxxinity celebrates trial success in early Parkinson’s therapy
Clinical Trials Arena
Vaxxinity
clinical trials
vaccines
Parkinson's Disease
UB-312
Flag link:
How ALS Cell Models That Began In Blood Spurred An Encouraging Early-Stage Clinical Trial
How ALS Cell Models That Began In Blood Spurred An Encouraging Early-Stage Clinical Trial
Forbes
clinical trials
innovation
ALS
Parkinson's Disease
Biogen
Flag link:
Biogen scraps late-stage study for Parkinson’s drug
Biogen scraps late-stage study for Parkinson’s drug
BioPharma Dive
Biogen
clinical trials
Parkinson's Disease
BIIB122
Flag link:
Top three unmet needs to target in Parkinson’s disease
Top three unmet needs to target in Parkinson’s disease
Clinical Trials Arena
Parkinson's Disease
drug devlopment
Flag link:
A Parkinson’s ‘game changer,’ backed by Michael J. Fox, could lead to new diagnostics and, someday, treatments
A Parkinson’s ‘game changer,’ backed by Michael J. Fox, could lead to new diagnostics and, someday, treatments
Stat
Parkinson's Disease
Michael J Fox
Flag link:
FTC says patent battle over Parkinson's drug could have 'significant implications' for patients
FTC says patent battle over Parkinson's drug could have 'significant implications' for patients
Endpoints
FTC
Parkinson's Disease
Apokyn
Supernus Pharmaceuticals
Sage Chemical
patents
Flag link:
Cerevel blames Covid for delayed neuroscience studies, says president is leaving
Cerevel blames Covid for delayed neuroscience studies, says president is leaving
Endpoints
Cerevel Therapeutics
COVID-19
epilepsy
Parkinson's Disease
darigabat
CVL-871
Flag link:
Working its way through a CRL on lead drug, Supernus taps $150M loan
Working its way through a CRL on lead drug, Supernus taps $150M loan
Endpoints
Supernus Pharmaceuticals
FDA
Parkinson's Disease
SPN-830
Flag link:
Inhibikase, FDA find common ground to lift hold on Parkinson's drug
Inhibikase, FDA find common ground to lift hold on Parkinson's drug
Fierce Biotech
Inhibikase Therapeutics
Parkinson's Disease
IkT-148009
clinical trials
Flag link:

Pages